What is Hibercell?
Hibercell operates as a specialized biopharmaceutical entity dedicated to the development of innovative therapies designed to combat cancer relapse and treatment resistance. By integrating traditional drug development methodologies with advanced computational expertise, the company focuses on exploiting stress-induced vulnerabilities in malignant cells. Its clinical-stage portfolio, which includes candidates such as HC-7366, HC-5404, and Odetiglucan, positions the firm as a key player in the precision oncology market. The company's strategic focus on the biological mechanisms of metastasis and therapeutic resistance addresses a significant unmet need in global healthcare, attracting substantial interest from both venture capital and institutional life science investors.
How much funding has Hibercell raised?
Hibercell has raised a total of $158.2M across 3 funding rounds:
Series A
$60.8M
Debt
$30M
Series B
$67.4M
Series A (2019): $60.8M with participation from Celgene Corporation, 6 Dimensions Capital, Hillhouse Capital, and ARCH Venture Partners
Debt (2021): $30M led by Hercules Capital
Series B (2021): $67.4M supported by Monashee Investment Management, ARCH Venture Partners, Tekla Healthcare Opportunities, Trinitas Capital Management, Huizenga Capital Management, Magnetic Ventures, Mount Sinai Health System, Bristol-Myers Squibb, and Hercules Capital
Key Investors in Hibercell
ARCH Venture Partners
A leading early-stage venture capital firm that specializes in creating and investing in life sciences and advanced technology companies, often co-founding startups with scientists to commercialize innovations.
Monashee Investment Management
A Boston-based financial services firm founded in 2011 that provides specialized investment advice and strategic capital management.
Hercules Capital
A specialty finance company headquartered in Palo Alto that provides senior secured venture growth loans to high-growth, innovative companies within the life sciences and technology sectors.
What's next for Hibercell?
With the recent infusion of capital, Hibercell is well-positioned to accelerate its clinical development programs and expand its research capabilities. The company's trajectory suggests a focus on advancing its lead therapeutic candidates through rigorous clinical trials while potentially exploring new strategic alliances to enhance its drug discovery platform. As the firm transitions further into its clinical-stage lifecycle, the emphasis will likely remain on validating its proprietary stress-targeting technology to improve patient outcomes. Continued support from high-profile life science investors provides the necessary runway to navigate the complex regulatory and development landscapes inherent in the oncology sector, setting the stage for potential future commercialization milestones.
See full Hibercell company page
